Vanguard Group
ANAB icon

Vanguard Group’s AnaptysBio ANAB Stock Holding History

Vanguard Group’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$74.9M Buy
1,544,037
+67,048
+5% +$2.61M ﹤0.01% 1980
2025
Q3 		$45.2M Sell
1,476,989
-60,561
-4% -$1.39M ﹤0.01% 2203
2025
Q2 		$34.1M Buy
1,537,550
+20,225
+1% +$423K ﹤0.01% 2303
2025
Q1 		$28.2M Sell
1,517,325
-326,415
-18% -$5.45M ﹤0.01% 2343
2024
Q4 		$24.4M Buy
1,843,740
+143,584
+8% +$3.48M ﹤0.01% 2503
2024
Q3 		$57M Buy
1,700,156
+275,750
+19% +$9.42M ﹤0.01% 2125
2024
Q2 		$35.7M Buy
1,424,406
+70,403
+5% +$1.64M ﹤0.01% 2283
2024
Q1 		$30.5M Sell
1,354,003
-26,112
-2% -$618K ﹤0.01% 2390
2023
Q4 		$29.6M Sell
1,380,115
-322,666
-19% -$5.57M ﹤0.01% 2419
2023
Q3 		$30.6M Sell
1,702,781
-72,916
-4% -$1.39M ﹤0.01% 2363
2023
Q2 		$36.1M Sell
1,775,697
-43,429
-2% -$880K ﹤0.01% 2340
2023
Q1 		$39.6M Buy
1,819,126
+42,218
+2% +$1.03M ﹤0.01% 2280
2022
Q4 		$55.1M Buy
1,776,908
+31,800
+2% +$898K ﹤0.01% 2140
2022
Q3 		$44.5M Buy
1,745,108
+14,638
+0.8% +$343K ﹤0.01% 2237
2022
Q2 		$35.1M Sell
1,730,470
-96,844
-5% -$2.15M ﹤0.01% 2365
2022
Q1 		$45.2M Sell
1,827,314
-15,369
-0.8% -$465K ﹤0.01% 2357
2021
Q4 		$64M Buy
1,842,683
+13,453
+0.7% +$427K ﹤0.01% 2216
2021
Q3 		$49.6M Sell
1,829,230
-54,911
-3% -$1.39M ﹤0.01% 2368
2021
Q2 		$48.9M Sell
1,884,141
-440,118
-19% -$10.5M ﹤0.01% 2382
2021
Q1 		$50.1M Buy
2,324,259
+103,938
+5% +$2.62M ﹤0.01% 2317
2020
Q4 		$47.7M Buy
2,220,321
+156,244
+8% +$3.79M ﹤0.01% 2225
2020
Q3 		$30.4M Sell
2,064,077
-191,503
-8% -$3.45M ﹤0.01% 2268
2020
Q2 		$50.4M Sell
2,255,580
-90,634
-4% -$1.66M ﹤0.01% 2010
2020
Q1 		$33.2M Buy
2,346,214
+151,553
+7% +$2.3M ﹤0.01% 2051
2019
Q4 		$35.7M Sell
2,194,661
-18,572
-0.8% -$439K ﹤0.01% 2257
2019
Q3 		$77.4M Buy
2,213,233
+228,089
+11% +$10.9M ﹤0.01% 1857
2019
Q2 		$112M Buy
1,985,144
+65,527
+3% +$4.72M ﹤0.01% 1687
2019
Q1 		$140M Buy
1,919,617
+30,416
+2% +$2.1M 0.01% 1567
2018
Q4 		$121M Buy
1,889,201
+37,271
+2% +$2.77M 0.01% 1570
2018
Q3 		$185M Buy
1,851,930
+308,517
+20% +$25.6M 0.01% 1441
2018
Q2 		$110M Buy
1,543,413
+288,792
+23% +$24.2M ﹤0.01% 1726
2018
Q1 		$131M Buy
1,254,621
+344,051
+38% +$38.8M 0.01% 1564
2017
Q4 		$91.7M Buy
910,570
+484,584
+114% +$35.7M ﹤0.01% 1767
2017
Q3 		$14.9M Buy
425,986
+219,955
+107% +$5.93M ﹤0.01% 2625
2017
Q2 		$4.93M Buy
206,031
+37,932
+23% +$953K ﹤0.01% 3088
2017
Q1 		$4.67M Buy
+168,099
New +$3.92M ﹤0.01% 3076

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group's ANAB Position: Q4 2025 in Review

Vanguard Group increased its AnaptysBio (ANAB) stake by 4.5% in Q4 2025, buying an estimated $2.61M and bringing the position to 1,544,037 shares worth $74.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1980.

Vanguard Group first reported a position in ANAB in Q1 2017 and has held it in 36 quarters since. The position peaked at $185M in Q3 2018. 179 funds tracked by Wall St. Rank hold ANAB as of Q4 2025.

  • Vanguard Group held 1,544,037 shares of AnaptysBio worth $74.9M as of Q4 2025.
  • Vanguard Group bought 67,048 AnaptysBio shares in Q4 2025, an estimated $2.61M.
  • AnaptysBio made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1980 holding.
  • Vanguard Group first reported a position in AnaptysBio in Q1 2017 and has held it in 36 quarters since.
  • Vanguard Group's AnaptysBio position peaked at $185M in Q3 2018.
  • 179 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.